ClinicalTrials.gg
Not yet recruitingNCT07940725SPARKUpdated Nov 18, 2026

Sotagliflozin to Lower Proteinuria in Recipients of a Kidney Transplant

A Phase 3 interventional study of Sotagliflozin and Placebo in Kidney Transplant and Albuminuria, sponsored by Finnian Mc Causland. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Finnian Mc Causland · Phase 3, Interventional, and Treatment

How we know

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Determine the effect of sotagliflozin versus placebo on the reduction in albuminuria from baseline to end of treatment (\~180 days) among adult patients with a stable kidney transplant.

Read the detailed description

Multicenter, randomized, double-blind, placebo-controlled trial to demonstrate the superiority of sotagliflozin at a dose of 200 milligrams daily, compared with placebo, on the reduction of the urine albumin:creatinine ratio (UACR) among kidney transplant recipients (KTRs)

02

Conditions studied

  • Kidney Transplant
  • Albuminuria

Browse trials for

Keywords

  • sotagliflozin
  • sglt2 inhibitor
  • kidney transplant
  • albuminuria
03

In context

Albuminuria

144 studies on the registry are indexed under Albuminuria; 25 are open to participants now.

This study's planned enrollment of 180 is above the median of 69 across 117 interventional studies indexed under Albuminuria.

Browse Albuminuria studies →

Lead sponsor

This is the only study on the registry with Finnian Mc Causland as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female KTRs aged ≥18 years
  • >6 months post kidney transplantation
  • Urine albumin/creatinine ratio >100mg/g
  • between ≥25 and ≤90 mL/min/1.73 m2
  • Stable allograft function

Exclusion criteria

Exclusion Criteria:

  • Signs or symptoms of volume depletion (including symptomatic hypotension \<90 mmHg systolic blood pressure)
  • Recurrent urinary tract infections (>2 episodes/year or antibiotic prophylaxis)
  • -proven acute rejection within 12 weeks
  • Uncontrolled hypertension (systolic blood pressure >180 or diastolic blood pressure >100 mmHg)
  • (NYHA) Class IV heart failure
  • Myocardial infarction, unstable angina, revascularization procedure (e.g., stent or bypass graft surgery), or cerebrovascular accident within 12 weeks
  • History of diabetic ketoacidosis
  • Type 1 Diabetes Mellitus
  • Hereditary glucose-galactose malabsorption or primary renal glucosuria
  • Liver disease (e.g., acute hepatitis, chronic active hepatitis, cirrhosis); (ALT) levels >2.0 times the (ULN) or total >1.5 times the ULN, unless consistent with Gilbert's disease; moderate to severe hepatic impairment based on the classification (class B or C)
  • antibody positive
  • Major surgery within 12 weeks
  • Atraumatic amputation within past 12 months of screening, or an active skin ulcer, osteomyelitis, gangrene, or critical ischemia of the lower extremity within 6 months of screening
  • Combination use of ACEi and ARB
  • Current use of an SGLT2 inhibitor (within 12 weeks prior to randomization)
  • Known allergies, , or intolerance to SGLT2i or its
  • Digoxin use with plasma level >1.2 ng/mL
  • Clofibrate, fenofibrate, dronedarone, or ranolazine treatment that has not been at a stable dose in the 30 days prior to screening or randomization, or a dose adjustment is expected
  • Current use of rifampin
  • Received an active drug (including vaccines) other than a placebo agent, or used an investigational medical device within 12 weeks before Day 1/baseline
  • Pregnant or breast-feeding or planning to become pregnant or breast-feed during the study
  • Women of * not willing to use a highly-effective method(s) of , or who are unwilling or unable to be tested for pregnancy
  • Any condition that in the opinion of the investigator would make participation not in the best interest of the subject
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Sotagliflozin

    Sotagliflozin at 200 mg daily via oral route for 180 days, followed by a 30 day off-drug period (total study time 210 days).

    Drug: Sotagliflozin

  • Placebo comparator
    Placebo

    Matching placebo once daily via oral route for 180 days, followed by a 30 day off-drug period (total study time 210 days).

    Drug: Placebo

Interventions

  • Eligible participants will be randomized in a 1:1 ratio to either sotagliflozin 200mg or matching placebo daily

  • DrugPlacebo

    Eligible participants will be randomized in a 1:1 ratio to either sotagliflozin 200mg or matching placebo daily

06

What researchers measure

Primary outcomes

  1. Change in albuminuria from baseline to end of treatment (~180 days)

    Primary Efficacy Outcome

    Time frame: 180 days

Secondary outcomes

  1. Total slope of eGFR from baseline to end of follow-up (~30 days post-cessation of randomized therapy) in mL/min/1.73 m2/year.

    Secondary Efficacy Outcome

    Time frame: 210 days

  2. Proportion of participants with a decline in UACR by 30% or greater from baseline to end of treatment (~180 days)

    Secondary Efficacy Outcome

    Time frame: 210 days

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Anonymized data will be shared with collaborating institutions to facilitate a pre-specified pooled analysis.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: November 10, 2027 through 6 months after study closeout.

Access criteria: Anonymized data will be shared under completed data use agreements to facilitate pre-specified pooled analyses.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2027; primary completion for Mar 2029, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 17, 2026
StartEst.
Mar 1, 2027
Primary completionEst.
Mar 1, 2029
CompletionEst.
Sep 1, 2029
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Secondary outcomes
2 edited
What changed in the outcomes
  • EditedtotalTotal slope of eGFR from baseline to end of follow-up (~30 days post-cessation of randomized therapy) in mL/min/1.73 m2/year.Time frame: 210 days
  • EditedDeclineProportion of participants with a decline in UACR by 30% or greater from baseline to end of treatment (~180 days)Time frame: 210 days
Nov 18, 2026
Registered
First appeared on the registry
Nov 17, 2026
Show all 2 updates
  1. Nov 18, 2026
    Secondary outcomes 2 edited
    What changed in the outcomes
    • EditedtotalTotal slope of eGFR from baseline to end of follow-up (~30 days post-cessation of randomized therapy) in mL/min/1.73 m2/year.Time frame: 210 days
    • EditedDeclineProportion of participants with a decline in UACR by 30% or greater from baseline to end of treatment (~180 days)Time frame: 210 days
  2. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07940725
Lead sponsor
Finnian Mc Causland
Responsible party
Finnian Mc Causland (Associate Physician, Brigham and Women's Hospital) — Sponsor-investigator
First posted
Nov 17, 2026
Start date
Mar 1, 2027 (estimated)
Primary completion
Mar 1, 2029 (estimated)
Completion
Sep 1, 2029 (estimated)
Last update
Nov 18, 2026

Study contacts

Finnian R Mc Causland, MBBCh, MMSc, FRCPI
Contact
fmccausland@bwh.harvard.edu
617-732-5500 ext. Pager 17993
Martina M McGrath, MBBCh
Contact
mmcgrath8@bwh.harvard.edu
617-732-5500 ext. Pager 13672
Finnian R Mc Causland, MBBCh, MMSc
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sotagliflozin

Start the discussion